StockData
Atea Pharmaceuticals, Inc. logo

Atea Pharmaceuticals, Inc. (AVIR) stock

AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$3.96+0.03 (+0.76%)

Close on Nov 20, 2026Market cap $317.61MP/E –Yield –

Atea Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Atea Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2022 was -$122.93M. For fiscal 2022 it was -$122.93M. The highest annual figure on record is $296.71M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2022Dec 31, 2022-$122.93M–
FY2021Dec 31, 2021-$87.01M-129.3%
FY2020Dec 31, 2020$296.71M–
FY2019Dec 31, 2019-$12.83M–
FY2018Dec 31, 2018-$7.92M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022-$21.55M-106.8%
Q3 FY2022Sep 30, 2022-$21.26M–
Q2 FY2022Jun 30, 2022-$21.07M–
Q1 FY2022Mar 31, 2022-$59.05M–
Q4 FY2020Dec 31, 2020$318.52M–
Q3 FY2020Sep 30, 2020-$9.50M–
Q4 FY2019Dec 31, 2019-$3.94M–

More Atea Pharmaceuticals figures

See a number that looks wrong?